Business Context and Reporting Period
Phibro Animal Health Corporation filed this Form 10-K for the fiscal year ended June 30, 2015. The supplied metadata references 2014 Q4, but the filing reports fiscal 2015 and includes quarterly data for the quarter ended June 30, 2015. Phibro develops, manufactures and sells animal health, mineral nutrition and performance products in more than 65 countries.
The company operates through Animal Health, Mineral Nutrition and Performance Products segments. Animal Health represented approximately 63% of fiscal 2015 sales and remains the principal earnings contributor.
Financial Performance and Key Metrics
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Net sales | $748.6 million | $691.9 million | Up 8% |
| Gross profit | $236.4 million | $207.8 million | Up 14% |
| Gross margin | 31.6% | 30.0% | Up 160 basis points |
| Operating income | $87.7 million | $63.8 million | Up 37% |
| Net income | $60.3 million | $(3.1) million | Returned to profitability |
| Diluted EPS | $1.51 | $(0.10) | Improved materially |
| Adjusted EBITDA | $110.0 million | $90.6 million | Up 21% |
| Operating cash flow | $68.7 million | $(0.7) million | Improved by $69.4 million |
| Capital expenditures | $20.1 million | $19.8 million | Up slightly |
FY2015 sales growth was led by Animal Health, up 9% to $470.8 million, and Mineral Nutrition, up 13% to $227.1 million. Performance Products declined 14% to $50.7 million. Animal Health Adjusted EBITDA increased 20% to $120.3 million; Mineral Nutrition increased 24% to $14.4 million; and Performance Products declined 43% to $2.6 million.
Fourth-quarter fiscal 2015 net sales were $185.0 million, gross profit was $60.8 million, operating income was $21.0 million and net income was $10.4 million. Fourth-quarter Adjusted EBITDA was $27.0 million.
At June 30, 2015, cash and cash equivalents were $29.2 million, working capital was $176.0 million and the current ratio was 2.62:1. Total debt was approximately $289.5 million, including $287.1 million of Term B debt and $3.0 million drawn on the revolving facility. The company reported $83.0 million of remaining revolver availability after borrowings and letters of credit.
Material Changes Versus the Prior Comparable Period
- Net sales increased $56.7 million, primarily from volume growth in Animal Health and Mineral Nutrition.
- Gross margin expanded due principally to Animal Health volume growth, operating efficiencies and favorable currency effects on production costs.
- Interest expense declined $18.7 million following the 2014 refinancing and retirement of higher-cost debt, including 9.25% senior notes.
- FY2014 included a $22.8 million loss on extinguishment of debt and a $5.4 million insurance-claim loss; neither was recorded in FY2015.
- FY2015 included $8.0 million of vaccine licensing milestone revenue and gross profit. Excluding this item, sales growth was approximately 7% and Adjusted EBITDA growth was approximately 13%.
- Cash flow benefited from the absence of FY2014 refinancing-related payments and unusually high interest payments, but inventories consumed $19.4 million of cash in FY2015.
- In January 2015, Phibro entered into vaccine collaboration, licensing and purchase arrangements with MJ Biologics. The transaction generated $9.2 million of intangible assets, included a $5.0 million upfront payment and a $5.0 million loan, and created future closing and earn-out obligations.
- Management and the independent auditor identified material weaknesses in internal control over financial reporting. Quarterly information for March 31, 2015 was restated for income-tax accounting errors relating to long-term intercompany investments.
Guidance, Outlook, Commentary and Risks
Management expects liquidity to be adequate based on cash, operating cash flow and financing arrangements. Fiscal 2016 capital expenditures were expected to be approximately $35 million, primarily for Animal Health capacity expansion and cost reductions. The filing does not provide formal revenue or earnings guidance.
- Antibacterials and related products are strategically important: medicated products represented approximately 45% of FY2015 net sales, and global MFAs and other sales were approximately $335.7 million.
- Management estimated that withdrawal of all U.S. non-therapeutic claims for medically important antibacterials, without replacement therapeutic claims, could have reduced FY2015 MFA and other sales by approximately $10 million to $15 million.
- FDA Veterinary Feed Directive requirements and related antimicrobial-use restrictions may increase compliance costs, reduce demand or limit product claims. Carbadox also remains subject to regulatory scrutiny concerning residues.
- A February 2015 FDA inspection produced a Form 483 observation concerning the uniform dispersion and stability of drug components. The company responded and stated that marketing had not been affected, but failure to resolve the matter could be material.
- Operations are exposed to foreign currency, particularly in Brazil and Israel, as well as political, economic, supply-chain, environmental and labor risks in those jurisdictions.
- Environmental liabilities include approximately $6.8 million of recorded accruals and $9.9 million of letters of credit supporting financial assurance. Potential liability related to the Omega Chemical Superfund groundwater plume cannot currently be estimated with certainty.
- Substantially all debt is floating-rate debt; a 100-basis-point increase in LIBOR was estimated to increase annual interest expense by approximately $0.6 million.
- The company is controlled by BFI, which held approximately 92.2% of combined voting power through the dual-class share structure. This limits public shareholders' influence over corporate matters.
Most Important Facts for Investors to Verify
- Confirm the applicable reporting period: this filing is for FY2015 and the quarter ended June 30, 2015, not a standalone 2014 Q4 filing.
- Reconcile reported sales and profitability with the $8.0 million vaccine licensing milestone and assess the sustainability of underlying growth.
- Monitor antimicrobial regulations, FDA claim realignment, VFD implementation and the ongoing carbadox review.
- Assess debt-service capacity, floating-rate exposure, covenant compliance and the April 2019 revolver and April 2021 Term B maturities.
- Evaluate remediation plans for the three material weaknesses and the implications of the March 2015 quarterly restatement.
- Review the MJB transaction's future minimum closing payment, service-related compensation, royalties and earn-out obligations.
- Assess environmental accrual adequacy and the unquantified potential liability associated with the Omega Chemical Site.
- Consider the concentration of voting power, controlled-company governance exemptions and the ability of Class B holders to convert shares into Class A stock.